Healthy Clinical Trial
Official title:
Food Trial to Evaluate the Safety and Tolerability of SBD111 in Health Adults
Verified date | April 2022 |
Source | Solarea Bio, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the trial is to determine if the synbiotic (prebiotic and probiotic), provided twice daily (capsule) is safe and tolerable in healthy adults.
Status | Completed |
Enrollment | 32 |
Est. completion date | February 5, 2022 |
Est. primary completion date | January 5, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent 2. Stated availability throughout entire study period and willingness to fulfill all details of the protocol 3. Age 18-70 4. Be in general good health as determined by a screening evaluation within 30 days of the first dose of SBD111 or placebo 5. Willing to comply with protocol and report on compliance and side effects during study period 6. Body Mass Index between 18.5 and 35 kg/m2 7. Normal cardiovascular parameters, systolic blood pressure = 155 mm Hg, diastolic blood pressure = 95 mm Hg) Exclusion Criteria: 1. Are currently taking probiotic or prebiotic supplements, or have taken them in the past 30 days 2. Unwilling to avoid probiotics/prebiotics supplements for the duration of the study 3. Known or suspected allergies to probiotics 4. Received oral or parenteral antibiotics within 3 months of enrollment or prescribed antibiotics on day of enrollment. 5. Major surgery or endoscopy within last 3 months. 6. Subject is a smoker 7. Subject has a history of drug and/or alcohol abuse at the time of enrolment 8. Presence of any of the following: 9. Abnormal vital signs or clinically significant systems abnormalities based on screening questionnaire 10. Indwelling catheter or implanted hardware/prosthetic device or feeding tube 11. Febrile illness (oral temperature >37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline visit (first dose of study drug) 12. Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, or inflammatory bowel disease 13. History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease 14. Underlying structural heart disease or previous history of endocarditis or valve replacement 15. Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy, neutrophil count <500/mm^3, or an anticipated drop in the neutrophil count to <500/mm3 16. History of cancer excluding non-melanoma skin cancers or cancer more than 10 years ago 17. History of collagen vascular disease 18. Active TB 19. Women only - pregnant, planning on becoming pregnant within the next 2 months, breastfeeding, positive urine pregnancy test during screening or within 24 hours of first dose of study drug. 20. Screening laboratory tests greater than upper normal limit (ULN) or less than lower normal limit (LLN): 1. WBCs < LLN or > ULN 2. Neutrophils < 1500/µl (1.5 x109/L) 3. Platelets < 100 x 10³/µl (100 x 109/L) 4. Haemoglobin < 9.0 g/dl (90 g/L) f. GFR of > 40 mL/minute g. AST > 3 x upper limit of normal h. ALT > 3 x upper limit of normal i. Total Bilirubin > 1.5 x upper limit of normal 21. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study. |
Country | Name | City | State |
---|---|---|---|
United States | Hinda and Arthur Marcus Institute for Aging Research | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Solarea Bio, Inc | Hebrew SeniorLife |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Composition and function of the gut microbiome and presence of SBD111 in stool specimens by shotgun metagenomic sequencing | Day-0 to Day-28 and Day-56 (washout) | ||
Primary | Safety as assessed by incidence of adverse advents | Occurrence of adverse events defined as a Grade II-IV toxicity (FDA's Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Subjects Enrolled in Preventative Vaccine Clinical Trials, September 2007), that are possibly or probably related to administration of SBD111 | day-0 to day-28 | |
Secondary | Gastrointestinal Tolerability as assessed by Gastrointestinal Tolerability Questionnaire | Occurrence of gastrointestinal intolerability symptoms defined as a Grade II-IV toxicity | day-0 to day-28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |